These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21705451)

  • 1. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.
    Mohler JL; Titus MA; Wilson EM
    Clin Cancer Res; 2011 Sep; 17(18):5844-9. PubMed ID: 21705451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.
    Mohler JL; Titus MA; Bai S; Kennerley BJ; Lih FB; Tomer KB; Wilson EM
    Cancer Res; 2011 Feb; 71(4):1486-96. PubMed ID: 21303972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
    Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrotestosterone synthesis pathways from inactive androgen 5α-androstane-3β,17β-diol in prostate cancer cells: Inhibition of intratumoural 3β-hydroxysteroid dehydrogenase activities by abiraterone.
    Ando T; Nishiyama T; Takizawa I; Ishizaki F; Miyashiro Y; Takeda K; Hara N; Tomita Y
    Sci Rep; 2016 Aug; 6():32198. PubMed ID: 27561382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
    Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
    J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
    Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
    J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
    Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5α-reductase type 3 enzyme in benign and malignant prostate.
    Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
    Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease.
    Bauman DR; Steckelbroeck S; Williams MV; Peehl DM; Penning TM
    Mol Endocrinol; 2006 Feb; 20(2):444-58. PubMed ID: 16179381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
    Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
    Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
    Rizner TL; Lin HK; Peehl DM; Steckelbroeck S; Bauman DR; Penning TM
    Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer.
    Ishizaki F; Nishiyama T; Kawasaki T; Miyashiro Y; Hara N; Takizawa I; Naito M; Takahashi K
    Sci Rep; 2013; 3():1528. PubMed ID: 23524847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of 5α-dihydrotestosterone from 5α-androstane-3α,17β-diol in prostate cancer LAPC-4 cells - Identifying inhibitors of non-classical pathways producing the most potent androgen.
    Boutin S; Roy J; Maltais R; Poirier D
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126783. PubMed ID: 31753699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3.
    Provost PR; Blomquist CH; Godin C; Huang XF; Flamand N; Luu-The V; Nadeau D; Tremblay Y
    Endocrinology; 2000 Aug; 141(8):2786-94. PubMed ID: 10919264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
    Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
    J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
    Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
    Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
    Li Z; Bishop AC; Alyamani M; Garcia JA; Dreicer R; Bunch D; Liu J; Upadhyay SK; Auchus RJ; Sharifi N
    Nature; 2015 Jul; 523(7560):347-51. PubMed ID: 26030522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Stanczyk FZ; Azen CG; Pike MC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.